Physician profile

Mark Lii

Optometrist · Santa Fe Springs, CA

NPI 1902338288

$1,605.19

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$101.54

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Aerie Pharmaceuticals, INC. $372.00 2019-2021
Allergan, INC. $329.07 2019-2020
Sun Pharmaceutical Industries INC. $250.22 2019-2021
Kala Pharmaceuticals, INC. $180.54 2019-2021
Bausch & Lomb, A Division of Bausch Health US, LLC $162.40 2019-2021
Abbvie INC. $101.54 2024
Shire North American Group INC $94.63 2019
Eyevance Pharmaceuticals LLC $60.17 2019-2021
Novartis Pharmaceuticals Corporation $36.21 2019-2020
Akorn, INC. $18.41 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Lii

$1,605.19

in general payments reported 2019-2025

Years
2019-2024
Top company
Aerie Pharmaceuticals, INC.

https://glasscript.com/doctor/3496947/mark-lii

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.